OTC •
Healthcare •
Drug Manufacturers - Specialty & Generic •
Quote as of 05/13/2026 15:49
Company Profile
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
ExchangeOTC
Market Capitalization16,610 mln
Float222 mln
Earnings Date04/28/2026
EPS
0.14
Overpriced
P / E
171
Highly speculative
Piotroski F-Score
6
/ 9
Solid
Beneish M-Score
-2.62
Likely reliable
1-Year Forecast
28.00
Fairly priced
Relative Strength
97
/ 100
Top performer
Business Description
Swedish Orphan Biovitrum (Sobi) is a Swedish pharmaceutical company founded in 1939 and based in Stockholm, serving patients across Europe, North America, the Middle East, Asia, and Australia. The company focuses on rare and serious diseases, offering a broad range of specialty medicines that treat conditions such as haemophilia, immune disorders, and certain blood cancers. Sobi works alongside partners including Sanofi, Apellis Pharmaceuticals, and ADC Therapeutics to develop and deliver these treatments to patients who have few or no other options.